YS
Income statement / Annual
Last year (2025), YS Biopharma Co., Ltd.'s total revenue was $614.96 M,
an increase of 7.24% from the previous year.
In 2025, YS Biopharma Co., Ltd.'s net income was -$99.98 M.
See YS Biopharma Co., Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
03/31/2025 |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
| Operating Revenue |
$614.96 M |
$573.42 M |
$687.20 M |
$502.95 M |
$257.02 M |
| Cost of Revenue |
$107.77 M
|
$117.69 M
|
$153.36 M
|
$117.07 M
|
$59.66 M
|
| Gross Profit |
$507.19 M
|
$455.73 M
|
$533.84 M
|
$385.88 M
|
$197.36 M
|
| Gross Profit Ratio |
0.82
|
0.79
|
0.78
|
0.77
|
0.77
|
| Research and Development Expenses |
$146.37 M
|
$302.80 M
|
$318.70 M
|
$211.22 M
|
$94.39 M
|
| General & Administrative Expenses |
$135.99 M
|
$147.65 M
|
$81.76 M
|
$107.05 M
|
$138.89 M
|
| Selling & Marketing Expenses |
$254.74 M
|
$280.45 M
|
$251.56 M
|
$165.72 M
|
$69.44 M
|
| Selling, General & Administrative Expenses |
$390.73 M
|
$428.09 M
|
$333.32 M
|
$272.77 M
|
$208.33 M
|
| Other Expenses |
$56.38 M
|
$170.67 M
|
-$199.45 K
|
-$2.41 M
|
-$22.36 M
|
| Operating Expenses |
$593.48 M
|
$901.56 M
|
$647.15 M
|
$549.18 K
|
$319.68 M
|
| Cost And Expenses |
$701.25 M
|
$1.02 B
|
$800.51 M
|
$549.18 K
|
$379.33 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$15.74 M
|
$44.34 M
|
$30.86 M
|
$2.72 M
|
$29.69 M
|
| Depreciation & Amortization |
$36.65 M
|
$42.19 M
|
$36.69 M
|
$31.15 M
|
$27.91 M
|
| EBITDA |
-$48.54 M |
-$368.66 M |
-$76.80 M |
-$67.20 M |
-$116.78 M |
| EBITDA Ratio |
-0.08
|
-0.64
|
-0.11
|
-0.13
|
-0.45
|
| Operating Income Ratio |
-0.14
|
-0.78
|
-0.2
|
-0
|
-0.49
|
| Total Other Income/Expenses Net |
-$14.64 M
|
-$9.36 M
|
-$4.96 M
|
$17.89 M
|
-$48.52 M
|
| Income Before Tax |
-$100.93 M
|
-$455.19 M
|
-$144.35 M
|
-$545.73 K
|
-$174.37 M
|
| Income Before Tax Ratio |
-0.16
|
-0.79
|
-0.21
|
-0
|
-0.68
|
| Income Tax Expense |
-$946.87 K
|
-$21.73 M
|
$1.13 M
|
$4.94 M
|
$17.45 M
|
| Net Income |
-$99.98 M
|
-$433.46 M
|
-$145.48 M
|
-$545.73 K
|
-$191.83 M
|
| Net Income Ratio |
-0.16
|
-0.76
|
-0.21
|
-0
|
-0.75
|
| EPS |
-0.94 |
-4.05 |
-1.88 |
-0.0185 |
-6.67 |
| EPS Diluted |
-0.94 |
-4.05 |
-1.88 |
-0.0185 |
-6.67 |
| Weighted Average Shares Out |
$106.92 M
|
$106.92 M
|
$77.42 M
|
$29.50 M
|
$28.75 M
|
| Weighted Average Shares Out Diluted |
$106.92 M
|
$106.92 M
|
$77.42 M
|
$29.50 M
|
$28.75 M
|
| Link |
|
|
|
|
|
